ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.43
0.17%
US Tech 100
20,733.20
0.80%
S&P 500
6,051.33
0.65%
US Dollar vs CAD
1.43954
-0.05%
Bitcoin
102,667.87
0.59%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) Share Price

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.46
-0.06
( -3.95% )
Updated: 10:30:17
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.46
Bid
1.45
Ask
1.47
Volume
26,309
1.46 Day's Range 1.50
1.22 52 Week Range 1.94
Market Cap
70.457M
Previous Close
1.52
Open
1.50
Last Trade
100
@
1.46
Last Trade Time
10:51:02
Financial Volume
US$ 39,080
VWAP
1.4854
Average Volume (3m)
220,135
Shares Outstanding
48,258,111
Dividend Yield
-
PE Ratio
-1.05
Earnings Per Share (EPS)
-1.41
Revenue
9.16M
Net Profit
-68.17M

About Ikena Oncology Inc

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.ikenaoncology.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was US$1.52. Over the last year, Ikena Oncology shares have traded in a share price range of US$ 1.22 to US$ 1.94.

Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is US$73.35 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -1.05.

Ask ADVFN Intelligence (AI)

IKNA Latest News

More News

Form 425 - Prospectuses and communications, business combinations

January 10 2025
Edgar (US Regulatory)

Form 425 - Prospectuses and communications, business combinations

December 23 2024
Edgar (US Regulatory)

Form 8-K - Current report

December 23 2024
Edgar (US Regulatory)

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The...

December 23 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 14 2024
Edgar (US Regulatory)

Ikena Oncology Reports Third Quarter 2024 Financial Results

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided...

November 07 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 07 2024
Edgar (US Regulatory)

Ikena Oncology Reports Second Quarter 2024 Financial Results

BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an...

August 08 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

July 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-1.351351351351.481.531.46892001.49965468CS
4-0.13-8.176100628931.591.71.451478601.58081713CS
12-0.26-15.11627906981.721.941.452201351.64116598CS
26-0.24-14.11764705881.71.941.451280871.65604472CS
520.139.774436090231.331.941.222336721.53625447CS
156-7.77-84.18201516799.2311.791.021701133.00683856CS
260-20.94-93.482142857122.437.611.021674125.71158033CS

IKNA - Frequently Asked Questions (FAQ)

What is the current Ikena Oncology share price?
The current share price of Ikena Oncology is US$ 1.46
How many Ikena Oncology shares are in issue?
Ikena Oncology has 48,258,111 shares in issue
What is the market cap of Ikena Oncology?
The market capitalisation of Ikena Oncology is USD 73.35M
What is the 1 year trading range for Ikena Oncology share price?
Ikena Oncology has traded in the range of US$ 1.22 to US$ 1.94 during the past year
What is the PE ratio of Ikena Oncology?
The price to earnings ratio of Ikena Oncology is -1.05
What is the cash to sales ratio of Ikena Oncology?
The cash to sales ratio of Ikena Oncology is 7.85
What is the reporting currency for Ikena Oncology?
Ikena Oncology reports financial results in USD
What is the latest annual turnover for Ikena Oncology?
The latest annual turnover of Ikena Oncology is USD 9.16M
What is the latest annual profit for Ikena Oncology?
The latest annual profit of Ikena Oncology is USD -68.17M
What is the registered address of Ikena Oncology?
The registered address for Ikena Oncology is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Ikena Oncology website address?
The website address for Ikena Oncology is www.ikenaoncology.com
Which industry sector does Ikena Oncology operate in?
Ikena Oncology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SLXNSilexion Therapeutics Corporation
US$ 1.2174
(109.90%)
175.96M
RNAZTransCode Therapeutics Inc
US$ 12.00
(75.70%)
18.01M
YIBOPlanet Image International Ltd
US$ 4.96
(61.04%)
48.81M
BACKIMAC Holdings Inc
US$ 1.169
(41.01%)
52.81M
RFACRF Acquisition Corporation
US$ 6.91
(38.20%)
61.05k
LPTXLeap Therapeutics Inc
US$ 0.6395
(-71.58%)
8.11M
STSSSharps Technology Inc
US$ 0.4361
(-70.13%)
11.78M
SABSSAB Biotherapeutics Inc
US$ 2.205
(-49.43%)
940.79k
MGOLMGO Global Inc
US$ 0.1751
(-38.13%)
14.79M
INKTMiNK Therapeutics Inc
US$ 6.4159
(-27.41%)
67.48k
NVDANVIDIA Corporation
US$ 121.48
(2.58%)
249.48M
HEPAHepion Pharmaceuticals Inc
US$ 0.2232
(35.27%)
233.22M
SLXNSilexion Therapeutics Corporation
US$ 1.2136
(109.24%)
175.96M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.5085
(23.39%)
135.5M
TRIBTrinity Biotech PLC
US$ 1.0496
(38.11%)
98.92M

IKNA Discussion

View Posts
Monksdream Monksdream 1 month ago
IKNA under $2
👍️0
Monksdream Monksdream 3 months ago
IKNA under $2
👍️0
Monksdream Monksdream 6 months ago
IKNA under $2
👍️0
Monksdream Monksdream 6 months ago
IKNA under $2
👍️0
Monksdream Monksdream 7 months ago
IKNA under $2
👍️0
glenn1919 glenn1919 8 months ago
IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 months ago
IKNA under $2=
👍️0
Monksdream Monksdream 11 months ago
IKNA under $2
👍️0
herbied47 herbied47 1 year ago
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 1 year ago
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 1 year ago
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 1 year ago
what happened here my short friend
👍️0
Tacostocks Tacostocks 1 year ago
Aged like milk eh
👍️0
AJ Freely AJ Freely 1 year ago
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 2 years ago
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA monster
👍️0
crudeoil24 crudeoil24 4 years ago
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

Your Recent History

NASDAQ
IKNA
Ikena Oncology
BIT
S24958
SG ISSUER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads